Michigan Medicine Annual Hematologic Malignancies Symposium

Saturday, October 19, 2024, 7:00 AM - 4:30 PM EST, Kensington Hotel, Ann Arbor, MI


AMA PRA Category 1 Credits™ (7.25 hours), Non-Physician Attendance (7.25 hours)

The University of Michigan Rogel Cancer Center (UMRCC) is an NCI-designated comprehensive cancer center with a history of excellence in cancer care, education, and research. The UMRCC catchment area includes the entire State of Michigan, its 10M residents, and 750 community medical oncologists. After completing this activity participants will be able to utilize current, state of the art updates in the diagnosis, risk stratification, and treatment of all hematologic malignancies. They will also be able to enroll patients to the ground breaking and often lifesaving clinical trials. After completion of this activity, patient outcomes will be improved by having been enrolled in the appropriate clinical trials designed specifically to treat Hematologic Malignancies.

The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

For questions or concerns, please contact:
Jennifer Fossum

Accessibility Statement
 
The University of Michigan Medical School is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require special accommodations, including dietary concerns, please contact the CME Activity Coordinator.

Mitigation of Relevant Financial Relationships

The University of Michigan Medical School adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners, or others are required to disclose all relevant financial relationships with ineligible entities. All relevant financial relationships have been mitigated prior to the commencement of the activity.

Saturday, October 19, 2024